Ader: An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial [HCQ]

An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-beta-1a and hydroxychloroquine in hospitalized patients with COVID-19 - Final results from the DisCoVeRy trial

Ader et al., medRxiv, doi:10.1101/2022.02.16.22271064 (Preprint)

Ader et al., An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus.., medRxiv, doi:10.1101/2022.02.16.22271064 (Preprint)

Oct 2020 Source PDF

Twitter
Facebook

All Studies Meta

Early terminated very late stage (95% on oxygen at baseline) DISCOVERY trial. 4% more patients were on ventilation at baseline in the HCQ group. This preprint presents more recent results than the earlier journal article. This study is excluded in the after exclusion results of meta analysis: very late stage, >50% on oxygen/ventilation at baseline.

Important missing comments or errors? Let us know.

risk of death, 15.3% higher, RR 1.15, p = 0.70, treatment 11 of 150 (7.3%), control 13 of 149 (8.7%), adjusted per study, odds ratio converted to relative risk, day 90.

risk of death, 10.1% lower, RR 0.90, p = 0.75, treatment 15 of 150 (10.0%), control 13 of 149 (8.7%), adjusted per study, odds ratio converted to relative risk, day 28.

risk of no viral clearance, 23.8% lower, RR 0.76, p = 0.68, treatment 4 of 83 (4.8%), control 5 of 81 (6.2%), NNT 74, odds ratio converted to relative risk, Table S2, day 29.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

Ader et al., 6 Oct 2020, Randomized Controlled Trial, multiple countries, preprint, baseline oxygen required 95.4%, 59 authors, study period 22 March, 2020 - 29 June, 2020, average treatment delay 9.0 days.

Contact: florence.ader@chu-lyon.fr.

All Studies Meta Analysis Submit Updates or Corrections

This Paper HCQ All

Abstract: medRxiv preprint doi: https://doi.org/10.1101/2022.02.16.22271064; this version posted February 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . Title An open-label randomized, controlled trial of the effect of lopinavir/ritonavir, lopinavir/ritonavir plus IFN-β-1a and hydroxychloroquine in hospitalized patients with COVID-19 – Final results from the DisCoVeRy trial. Authors ADER1,2, Florence PEIFFER-SMADJA3,4,5, Nathan BOUSCAMBERT-DUCHAMP7,8, BELHADI3,9, Drifa Julien Alpha POISSY6, DIALLO10, Maude Christelle DELMAS11, Juliette SAILLARD11, Aline DECHANET12, Noémie MERCIER10, Axelle DUPONT9,12, Toni ALFAIATE9,12, François-Xavier LESCURE3,4, François RAFFI14,15, François GOEHRINGER16, Antoine KIMMOUN17, Stéphane JAUREGUIBERRY18,19, Jean REIGNIER20, Saad NSEIR6, François DANION21, Raphael CLERE-JEHL22,23, Kévin BOUILLER24,25, Jean-Christophe NAVELLOU26, Violaine TOLSMA27, André CABIE28,29 Clément DUBOST30,31, Johan COURJON32,33, Sylvie LEROY34,35,36, Joy MOOTIEN37, GACI38, Rostane Bruno MOURVILLIER39,40, Emmanuel FAURE41,42, Valérie POURCHER43,44, Sébastien GALLIEN45,46, Odile LAUNAY47, Karine LACOMBE43,48, JeanPhilippe LANOIX49,50, Alain MAKINSON51,52, Guillaume MARTIN-BLONDEL53,54, Lila BOUADMA3,55, Elisabeth 56,57,58 BRUNON BOTELHO-NEVERS56,57,58, ,59,60,61 , Olivier EPAULARD Amandine 62,63 , Lionel PIROTH GAGNEUX- , Florent WALLET64, Jean- Christophe RICHARD65,66, Jean REUTER67, Thérèse STAUB68, Bruno LINA7,8, Marion NORET69, Claire ANDREJAK70, Minh Patrick LÊ71,72, Gilles PEYTAVIN3,71, Maya HITES73, Dominique COSTAGLIOLA**43, Yazdan YAZDANPANAH**3,4, Charles BURDET***3,9,12, France MENTRE***3,9,12, on behalf of the DisCoVeRy study group#. ** co-before-last authors *** co-last authors # Full list in the Supplementary Appendix Author affiliations 1 Hospices Civils de Lyon, Département des maladies infectieuses et tropicales, F-69004, Lyon, France. 2 Centre International de Recherche en Infectiologie (CIRI), Inserm 1111, Université Claude Bernard Lyon 1, CNRS, UMR5308, École Normale Supérieure de Lyon, Univ Lyon, F69007, Lyon, France. 3 Université de Paris, IAME, INSERM, F-75006 Paris, France. Page 1 of 29 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2022.02.16.22271064; this version posted February 21, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 4 AP-HP, Hôpital Bichat, Service de maladies infectieuses et tropicales, F-75018 Paris, France. 5 National Institute for Health Research, Health Protection Research Unit in Healthcare Associated Infections and Antimicrobial Resistance, Imperial College London, London, UK. 6 Université de Lille, Inserm U1285, CHU Lille, Pôle de réanimation, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France. 7 Laboratoire de Virologie, Institut des Agents Infectieux de Lyon, Centre National de Référence des virus respiratoires France Sud, Hospices Civils de Lyon, F-69317,..

Late treatment
is less effective

Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit